Loading...
•
Sep 30, 2021
BioNano Q3 2021 Earnings Report
Bionano Genomics reported a strong Q3 2021 with record Saphyr shipments and installations and a significant revenue increase.
Key Takeaways
Bionano Genomics reported a 112% year-over-year increase in total revenue, reaching $4.7 million in Q3 2021. The company expanded its installed base of Saphyr systems and closed the acquisition of BioDiscovery, transitioning into a data solutions provider. They ended the quarter with $326.1 million in cash and short-term investments.
Total revenue increased by 112% year-over-year to $4.7 million.
Expanded the installed base of Saphyr systems from 121 to 141.
Closed acquisition of BioDiscovery, transforming into a data solutions provider.
Ended the quarter with $326.1 million in cash and short-term investments.
Revenue by Segment
Forward Guidance
Bionano Genomics anticipates achieving several milestones by the end of 2021, focusing on driving global adoption of Saphyr and advancing research and development initiatives.
Positive Outlook
- Interim publication of results from pediatric clinical study in Q4 2021.
- Validation of LDTs by 3 sites in both prenatal and pediatric clinical studies in Q4 2021.
- Initial prototype of next gen high throughput Saphyr in Q4 2021.
- Reach installed base of 150 systems to achieve a 50% increase over year end 2020 in Q4 2021.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...